Skip to main content
05_Bernardo_Franklin
© Photo: Bruna Guerra Photography

News categories: Honors & Funding

ERC Proof of Concept Grants for UNBIAS

European Research Council is supporting the journey from basic research to application

Prof. Bernardo Franklin from the Institute of Innate Immunity at the University Hospital Bonn has been awarded a Proof of Concept Grant by the European Research Council (ERC) as part of a program designed to help researchers translate their ideas from previous ERC projects into commercial applications. The project is awarded with a funding of €150,000, provided over a period of around one year.

ImmunoSensation2 member Prof. Dr. Bernardo S. Franklin studies hematopoietic stem cells (HSCs), which develop into different blood cells through processes of cell division and differentiation. “Bouts of inflammation that a person experiences as they get older will damage these stem cells,“ Bernardo S. Franklin says. “Processes like this cause hyperactivation of the innate immune system in the elderly.” This phenomenon, known as “inflammaging,” increases the risk of conditions including cardiovascular disease, diabetes and cancer, he adds.

“Wiping” the immune system’s harmful memories of inflammation


The project that has now secured ERC funding, which is entitled “Nanobodies to prevent hematopoietic stem cell bias and hyper-inflammation” (UNBIAS), aims to return HSCs to their original state in order to “wipe” the immune system’s harmful memories of inflammation. The researchers are using customized “mini-antibodies” known as nanobodies to achieve this. These antibodies, which are very small in relative terms, are taken from the blood of alpacas and can break up the places where inflammation develops.

Back in 2017, Franklin received a much-sought-after Starting Grant from the ERC worth some €1.5 million in funding. The Proof of Concept Grant will now build on this work already done. “Our aim is to validate the use of nanobodies to combat inflammaging and license this technology or its applications for industrial partners,” Franklin says. He believes that the project has the potential to alleviate the effects of inflammation and thus potentially save countless lives and the economic cost of illness.

Contact

Prof. Dr. Bernardo S. Franklin

Institute for Innate Immunity

University Hospital Bonn

Phone +49 228 28751981

Email: franklin@uni-bonn.de

Related news

Kerstin Ludwig

News categories: Honors & Funding

Genome data to improve diagnosis and treatment of long Covid

Despite the many advances, there are still major gaps in the care of patients with long-term and post-COVID. The Institute of Human Genetics at the UKB in Bonn now begins a genomLC study as part of a BMG funding priority. The researchers want to help speed up the diagnosis of long- and post-COVID and identify possible biomarkers that could possibly also differentiate between subgroups of the diseases. To this end, the genomic data of those affected is being analyzed as part of a study using blood samples. The project is funded by the Federal Ministry of Health (BMG) with 1.34 million euros.
View entry
Reckzeh News

News categories: Honors & Funding

Creating Personalized Cancer Treatments

Bonn researchers aim to improve colon cancer treatment using 3D organoids and digital twins. Funded by the Federal Ministry of Education and Research (BMBF), a collaborative project involving the University of Bonn, the company ESQlabs and the University Hospital Bonn is seeking to refine the therapy recommendations given to colon cancer patients. To this end, “ISPOT-K” is merging organoids taken from patients with the power of digital twin technology.
View entry
Prof. Dr. Valentin Schäfer

News categories: Honors & Funding

Valentin Schäfer appointed to Specialized Ethics Committee

Prof. Valentin S. Schäfer, Head of the Section of Rheumatology at the University Hospital Bonn (UKB) and researcher at the University of Bonn, has been appointed to the newly created Specialized Ethics Committee for Special Procedures by State Secretary Dr. Thomas Steffen at the Federal Ministry of Health. The committee, which is based at the Federal Institute for Drugs and Medical Devices (BfArM), will begin its work on July 1, 2025 and is responsible for the ethical evaluation of complex clinical trials.
View entry

Back to the news overview